Preparation and in vitro evaluation of nabumetone colon target drug delivery system

Abstract

The aim of the present study is to formulate and evaluate pulsincap dosage form containing Nabumetone which may be targeted to colon for to treat osteoarthritis and rheumatoid arthritis. A controlled onset, pulsatile, chronopharmaceutical drug delivery system of Nabumetone was developed for, to delay the release of drug and hence delay the onset of drug action. To minimize the frequency of drug administration by developing a once daily therapy administered at bedtime and Patient convenience and compliance could be achieved. The formulations were subjected to flow properties and FTIR study. Based on the results obtained F12 containing 8% Croscarmellose sodium was considered as the optimum powder blend for fabrication of pulsincap capsule. It was observed that a proper lag time of 6 hours was maintained with minimal upper GIT drug release for the combination of Ethyl cellulose and HPMC K15M hydrogel plug in the 2:1. It was observed that as the concentration of Hydrophilic polymer was increased the release rate of drug was delayed and finally burst release of drug from the formulation occurred after lag time. So, basing on these observations, of all the 5 pulsincap formulations, P5F12 formulation containing hydrogel plug of ethyl cellulose & HPMC K15M in 2:1 ratio was selected as optimized pulsincap formulation. In conclusion, this system can be considered as one of the promising formulation techniques for preparing time specific drug delivery systems and in Chronotherapeutic management. From the preliminary trials it was concluded that it is possible to formulate the pulsatile drug delivery system by the design of time modified chronopharmaceutical formulation.